A team of scientists has created 3D-printed functional human islets using a novel bioink. These islets are pancreatic cells that produce insulin. This is a major breakthrough in developing a sustainable treatment for type 1 diabetes. This technology provides a more effective and less invasive treatment option.
The novel bioink is made out of a combination of alginate and decellularized human pancreatic tissue. This approach allowed the production of high-density and durable islets that remained functional and alive for up to 3 weeks. The islets also maintained a strong insulin response.
Typically, islet transplants are infused into the liver, a procedure that can result in cell loss and a lack of long-term success. In contrast, the 3D-printed islets can be implanted under the skin. The procedure only requires local anesthesia and a small incision, giving patients a comfortable and safer approach.
“Our goal was to recreate the natural environment of the pancreas so that transplanted cells would survive and function better,” explained lead author Dr. Quentin Perrier. “We used a special bioink that mimics the support structure of the pancreas, giving islets the oxygen and nutrients they need to thrive.”
The human islets are fragile and thus require gentler methods of printing. By fine-tuning key settings, such as using low pressure (30 kPa) and a slow printing speed (20 mm per minute), these delicate islets were created. The careful approach reduced physical stress on the islets, allowing them to keep their natural shape. Maintaining a natural shape has been a challenge in previous bioprinting attempts.
In laboratory tests, the cells showed a 90% survival rate. These islets were also more successful than current islet preparations in their response towards glucose, releasing more insulin when needed. After three weeks, the bioprinted islets showed a stronger reaction to blood sugar levels. The construct maintained its structure without breaking down or clumping, which was a major problem in previous approaches. The islets also featured a porous structure, allowing the flow of oxygen and nutrients into the embedded structure. This design helped maintain cell health and also facilitated vascularization. As a result, these islets survived for longer periods, and maintained functionality after implantation.
The team is now testing the islets in animal models. They are also exploring long-term storage options, such as cryopreservation, which can significantly increase the distribution of the therapy. Adapting the method for alternative sources of insulin-producing cells is also being tested. This experiment is crucial in overcoming donor shortages.
According to Dr. Perrier, although much work remains to be done, this novel bioprinting method has the potential to provide personalized, implantable therapy for diabetes. There are high hopes for the therapy’s success in clinical trials. If proven effective, this therapy can revolutionize the lives of millions who suffer from diabetes.
Copyright @smorescience. All rights reserved. Do not copy, cite, publish, or distribute this content without permission.
